Jürgen Wolf

9PUBLICATIONS
138CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 03, 2026
Rare Fusions, Real Targets: Ultraprecision Oncology in Lung Cancer.

|Jun 10, 2026
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses.

|Dec 19, 2025
Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.

Felix John, Lea Ruge, Malte Verheyen

|Jul 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.

Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki

|Apr 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.

Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti

|Apr 20, 2023
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.

Theresa Reutter, Jana Fassunke, Michael Püsken

Pageof 2

Frequent Collaborators

4 joint publications

Matthias Scheffler

3 joint publications

Jana Fassunke

3 joint publications

Sebastian Yves Friedrich Michels

3 joint publications

Reinhard Büttner